Nélida Salvador-Tormo

Nélida Salvador-Tormo

Auto-generated profile, based on publicly available information

Nélida Salvador-Tormo


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
MLMar Lorente
Mar Lorente
AGAna García-Casas
Ana García-Casas
NSNélida Salvador
Nélida Salvador
AMAngélica Martínez-López
Angélica Martínez-López
EGEstibaliz Gabicagogeascoa
Estibaliz Gabicagogeascoa
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
Post-translational modifications directly control protein activity and, thus, they represent an important means to regulate the responses of cells to different stimuli. Protein SUMOylation has recently been recognised as one such modification, and it has been associated with various diseases, including different types of cancer. However, the precise way that changes in SUMOylation influence the tumorigenic properties of cells remains to be fully clarified. Here, we show that blocking the SUMO pathway by depleting SUMO1 and UBC9, or by exposure to ginkgolic acid C15:1 or 2-D08 (two different SUMOylation inhibitors), induces cell death, also inhibiting the invasiveness of tumour cells. Indeed, diminishing the formation of SUMO1 complexes induces autophagy-mediated cancer cell death through increasing the expression of Tribbles pseudokinase 3 (TRIB3). Moreover, we found that blocking the SUMO pathway inhibits tumour cell invasion by decreasing RAC1 SUMOylation. These findings shed new light on the mechanisms by which SUMO1 modifications regulate the survival, and the migratory and invasive capacity of tumour cells, potentially establishing the bases to develop novel anti-cancer treatments based on the inhibition of SUMOylation.

Verified
Journal Article
Open access
PDF file
MKMagdalena Kusaczuk
Magdalena Kusaczuk
EAELENA TOVAR AMBEL
ELENA TOVAR AMBEL
PMPaola Martín-Cabrera
Paola Martín-Cabrera
MLMar Lorente
Mar Lorente
NSNélida Salvador-Tormo
Nélida Salvador-Tormo
MNMONIKA NAUMOWICZ
MONIKA NAUMOWICZ
Despite the increasing understanding of the pathogenesis of glioblastoma (GBM), treatment options for this tumor remain limited. Recently, the therapeutic potential of natural compounds has attracted great interest. Thus, dietary flavonoids quercetin (QCT) and kaempferol (KMF) were investigated as potential cytostatic agents in GBM. Moreover, the physicochemical properties of QCT and KMF, determining their bioavailability and therapeutic efficiency, were evaluated. We proved that both polyphenols significantly reduced the viability of GBM cells. We also demonstrated that both QCT and KMF evoked the cytotoxic effect in T98G cells via induction of apoptotic cell death as shown by increased activity of caspase 3/7 and caspase 9 together with an overexpression of the cleaved form of PARP. Apoptosis was additionally accompanied by the activation of stress responses in QCT- and KMF-treated cells. Both polyphenols caused oxidative stress and endoplasmic reticulum (ER) stress, as demonstrated by the increased generation of reactive oxygen species (ROS), deregulated expressions of superoxide dismutases (SOD2 and Sod1 on protein and transcriptomic levels, respectively), as well as an overexpression of ERO1α, GRP78, p-JNK, and an up-regulation of Chop, Atf4 and Atf6α genes. The antitumor effect of QCT and KMF was also confirmed in vivo, showing reduced growth of tumor xenografts in the chick chorioallantoic membrane (CAM) experiment. Moreover, electrophoretic light scattering (ELS) was used to measure the zeta potential of cell membranes upon exposition to QCT and KMF. Additionally, on the basis of existing physicochemical data, the drug-likeness score of QCT and KMF was evaluated. Analyses showed that both compounds accomplish Lipinski’s Rule of 5, and they both fit into the criteria of good central nervous system (CNS) drugs. Altogether, our data support the idea that QCT and KMF might be plausible candidates for evaluation as therapeutic agents in preclinical models of glioblastoma.

22 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AOAlba Orea-Soufi
Alba Orea-Soufi
SCSONIA CASTILLO-LLUVA
SONIA CASTILLO-LLUVA
NSNélida Salvador-Tormo
Nélida Salvador-Tormo
PMPaola Martín-Cabrera
Paola Martín-Cabrera
SRSilvia Recuero
Silvia Recuero
MLMar Lorente
Mar Lorente
Background: Tribbles pseudokinase 3 (TRIB3) has been proposed to both promote and restrict cancer generation and progression. However, the precise mechanisms that determine this dual role of TRIB3 in cancer remain to be understood. In this study we aimed to investigate the role of TRIB3 in luminal breast cancer, the most frequent subtype of this malignancy. Methods: We genetically manipulated TRIB3 expression in a panel of luminal breast cancer cell lines and analyzed its impact on cell proliferation, and the phosphorylation, levels, or subcellular localization of TRIB3 and other protein regulators of key signaling pathways in luminal breast cancer. We also analyzed TRIB3 protein expression in samples from luminal breast cancer patients and performed bioinformatic analyses in public datasets. Results: TRIB3 enhanced the proliferation and AKT phosphorylation in luminal A (HER2-) but decreased them in luminal B (HER2+) breast cancer cell lines. TRIB3 negatively regulated the stability of HER2 in luminal B breast cancer cell lines. TRIB3 expression was associated with increased disease-free survival and a better response to therapy in luminal breast cancer patients. Conclusions: Our findings support the exploration of TRIB3 as a potential biomarker and therapeutic target in luminal breast cancer.

1 August 2004 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CACarmen Avendaño
Carmen Avendaño
J. Carlos MenéndezJ. Carlos Menéndez
J. Carlos Menéndez
MBMaría Del Mar Blanco
María Del Mar Blanco
JFJesús Ángel de la Fuente
Jesús Ángel de la Fuente
SMSonia Manzanaro
Sonia Manzanaro
J. Carlos MenéndezJ. Carlos Menéndez
J. Carlos Menéndez

15 October 2026 in Cancer Discovery
Verified
Journal Article
Open access
NGNatalia García
Natalia García
RCRoberto Corchado-Cobos
Roberto Corchado-Cobos
RGRyan Ghorayeb
Ryan Ghorayeb
ABAdrián Blanco-Gómez
Adrián Blanco-Gómez
OPOriol Cunillera Puértolas
Oriol Cunillera Puértolas
JPJesús Pérez-Losada
Jesús Pérez-Losada
Breast cancer that arises in the postpartum period often carries a poor prognosis and urgently requires chemoprevention strategies, particularly for women at elevated risk. Here, we report that a single post-lactation dose of cabergoline, a dopaminergic agonist that blocks prolactin secretion, delays the onset and reduces the incidence of postpartum mammary cancer in K14-Cre; Brca1F/F, Trp53F/F mice. In these mice, cabergoline treatment remodels the mammary gland by potentiating involution, reducing ductal area and proliferation, and reversing T cell exhaustion, potentially through modulation of ion channel expression. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk. Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy.